Brokerage Firm Rating on Cara Therapeutics (CARA)

Cara Therapeutics (CARA) : 4 brokerage houses believe that Cara Therapeutics (CARA) is a Strong Buy at current levels. Zacks Investment Research suggests a Sell with a rank of 4.The median of all the 4 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

Cara Therapeutics (CARA) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $24 and the lowest price target forecast is $18. The average forecast of all the analysts is $22.25 and the expected standard deviation is $2.87.


For the current week, the company shares have a recommendation consensus of Buy. Cara Therapeutics (NASDAQ:CARA): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $6.06 and $5.89 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.09. The buying momentum continued till the end and the stock did not give up its gains. It closed at $6.02, notching a gain of 1.86% for the day. The total traded volume was 559,839 . The stock had closed at $5.91 on the previous day.

In a related news, Menzaghi Frederique Ph.D., officer (VP-Research & Development) of Cara Therapeutics, Inc., unloaded 6,000 shares at an average price of $9 on April 20, 2016. The total amount of the transaction was worth $54,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the bodys peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. CR845 is a peripherally-acting kappa opioid receptor agonist for the treatment of both acute and chronic pain. I.V. CR845 is an injectable version of its peripheral kappa opioid receptor agonist, which is designed to provide pain relief without stimulating mu opioid receptors. CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with these cannabinoid receptor subtypes, with no off-target activities.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.